Siyaram Recycli. (544047)

Score breakdown: P/E: 3/3 · ROCE: 1/2 · Growth: 0/2 · Dividend: 0/1

Key Financials

Strengths

• ROCE of 16.62% shows reasonably efficient capital use even in a weak period.
• P/E of 10.57 is modest, and market cap of ₹199 Cr is smaller than the latest quarter's sales of ₹212 Cr.
• Price of ₹90.08 is well below the 52-week high of ₹122.00, offering upside if earnings recover.
• Latest quarter revenue of ₹212 Cr indicates meaningful operating scale relative to the small market cap.

Concerns

• Sales growth of -13.77% and profit growth of -59.90% reflect severe business deterioration.
• Latest quarter net profit of only ₹3 Cr on ₹212 Cr sales implies a razor-thin net margin.
• Piotroski F-Score of 3/9 signals weak financial health and poor fundamental momentum.
• Zero dividend yield and missing data on book value, debt/equity, and promoter holding limit balance-sheet assessment.

AI Analysis

I approach Siyaram Recycli with caution. A 59.90% drop in profit and 13.77% fall in sales are not signs of a franchise I can confidently hold. The latest quarter shows ₹212 Cr of revenue but just ₹3 Cr of net profit; that is a razor-thin margin, and it tells me there is little pricing power or operating leverage protecting the bottom line. ROCE at 16.62% is respectable, but with earnings collapsing and a Piotroski F-Score of only 3/9, the financial health is weaker than the headline valuation suggests. At ₹90.08, the P/E is 10.57, but that P/E is based on depressed earnings. If profits continue to slide, the headline multiple can quickly become less cheap. The market cap is only ₹199 Cr, smaller than the latest quarter's sales of ₹212 Cr, so there is a business here, but I need evidence that sales stabilise and margins recover. I also dislike the absence of a dividend: as a shareholder, I am entirely dependent on capital appreciation, which makes the cyclical risk larger. The 52-week range of ₹31.95 to ₹122.00 shows how volatile this stock is. I cannot calculate book value, ROE, debt/equity or promoter holding from the data given; that lack of transparency makes me want a wider margin of safety. This looks like a cyclical industrial business in a downcycle. I would not call it a wonderful business at a fair price; at best it is a mediocre business priced for recovery. I need several quarters of stable or improving sales, better profit conversion, and a stronger Piotroski score before I commit capital.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer